Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Dose Calibration of BCG-PPD
NCT06975774Phase 1Completed
- Sponsor
- Zhifei Biological
- Start
- Jul 2023
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bacillus calmette-guérin purified protein derivative in pulmonary tuberculosis (TB) (2 arms), sponsored by Zhifei Biological. Primary endpoints: Injection-site reaction endpoint at 72 hours and Safety endpoint at 72 hours. Started Jul 2023; status: completed.
02
Drugs
bacillus calmette-guérin purified protein derivative
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT06975774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975774.